香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Vigonvita Life Sciences Co., Ltd. 蘇州旺山旺水生物醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2630） 自願公告 與先聲藥業就氫溴酸氘瑞米德韋(VV116)新適應症訂立許可協議 本公告由蘇州旺山旺水生物醫藥股份有限公司（「本公司」或「旺山旺水」）自願作 出，以告知本公司股東及潛在投資者本集團最新業務發展狀況。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司與先聲藥業集團有限公司 （「先聲藥業」）就VV116新適應症訂立許可協議（「該協議」）。根據該協議，本公司 將授予先聲藥業VV116在大中華區抗呼吸道合胞病毒（「RSV」）感染以及抗人偏肺 病毒（「HMPV」）感染適應症的獨家許可權益。旺山旺水與先聲藥業強強聯合，發 揮各自研發、生產及商業化的優勢，加速VV116的臨床開發和商業化進程，以期 惠及更多患者。 關於VV116 VV1 ...

Group 1 - The Hong Kong biotechnology sector experienced a widespread decline, with notable drops in several companies' stock prices [1] - Specifically, Gilead Sciences-B fell over 13%, while Sanofi-B dropped more than 10% [1] - Other companies such as Crystal Technology Holdings and Hualing Pharmaceutical-B also saw declines exceeding 6% [1] Group 2 - Gilead Sciences-B's latest price is 11.750, with a market capitalization of 116.56 billion and a year-to-date increase of 290.37% [2] - Sanofi-B's latest price is 7.000, with a market capitalization of 7.44 billion and a year-to-date increase of 102.31% [2] - Crystal Technology Holdings has a latest price of 9.330, a market capitalization of 401.48 billion, and a year-to-date increase of 56.02% [2] - Hualing Pharmaceutical-B's latest price is 3.230, with a market capitalization of 34.13 billion and a year-to-date increase of 121.23% [2] - Other companies like Wangshan Wangshui-B and Sanleaf Biotech-B also reported significant declines, with year-to-date increases of 123.25% and 920.75% respectively [2]

Core Insights - The Hong Kong IPO market showed a marginal recovery in November 2025, with a notable concentration of listings towards the end of the month [2][18] - A total of 53 companies submitted listing applications, with 25 of them in the last week of November [2][18] - 12 new companies successfully listed on the Hong Kong Stock Exchange during this period [2][18] Listing Performance - The top three performers on their first trading day were 旺山旺水 (Wangshan Wangshui) with a gain of 145.73%, 明略科技 (Minglue Technology) at 106.10%, and 量化派 (Quantitative Party) at 88.78% [2][19][21] - Conversely, the companies with the largest declines were 海伟股份 (Haiwei Co.) at -22.97%, 文远知行 (Wenyan Zhixing) at -9.96%, and 小马智行 (Xiaoma Zhixing) at -9.28% [2][19][21] Fundraising Highlights - The top three companies in terms of fundraising were 赛力斯 (Sailis) with approximately 14.283 billion HKD, 小马智行 (Xiaoma Zhixing) at 6.707 billion HKD, and 创新实业 (Innovation Industry) at 5.495 billion HKD [2][19][26]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 蘇州旺山旺水生物醫藥股份有限公司（「本公司」） 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02630 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 66,677,133 | RMB | | 1 RMB | | 66,677,133 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 66,677,133 | RMB | | 1 RMB | | 66,677,133 | | 2. 股份分類 | 普通股 | 股份類別 ...

Core Viewpoint - The company has announced the implementation of H-share full circulation, converting approximately 100.2 million unlisted shares held by 10 shareholders into H-shares, which represents about 59.7983% of the total issued shares as of the announcement date [1] Group 1 - The board of directors approved the proposal for H-share full circulation on November 26, 2025 [1] - The conversion involves shares held by 10 shareholders, totaling approximately 100.2 million shares [1] - The H-share full circulation will significantly increase the liquidity of the company's shares in the market [1]

Core Viewpoint - The company has announced the implementation of H-share full circulation, converting 100 million unlisted shares held by 10 shareholders into H-shares, which represents approximately 59.7983% of the total issued shares as of the announcement date [1] Group 1 - The board of directors approved the proposal for H-share full circulation on November 26, 2025 [1] - The conversion of unlisted shares into H-shares is subject to obtaining all necessary approvals, including filing with the China Securities Regulatory Commission [1] - The company will apply for the listing and trading of these H-shares on the main board of the Stock Exchange of Hong Kong [1] Group 2 - The conversion and listing do not require shareholder approval according to the company's articles of association [1]

Core Viewpoint - The company Wangshan Wangshui-B (02630) announced the implementation of a proposal for full circulation of H-shares, converting 100 million unlisted shares held by 10 shareholders into H-shares, which represents approximately 59.7983% of the total issued shares as of the announcement date [1] Group 1 - The board of directors approved the proposal for full circulation of H-shares on November 26, 2025 [1] - The conversion of the 100 million unlisted shares into H-shares is subject to obtaining all relevant approvals, including filing with the China Securities Regulatory Commission [1] - The company will apply to the Stock Exchange for approval for the listing and trading of the converted H-shares on the main board [1] Group 2 - According to the company's articles of association, the conversion and listing do not require approval from the shareholders' meeting [1]

（股份代號：2630） 內幕消息 本公司建議實施H股全流通 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Vigonvita Life Sciences Co., Ltd. 蘇州旺山旺水生物醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 承董事會命 蘇州旺山旺水生物醫藥股份有限公司 董事長、執行董事、首席執行官兼總經理 本公告乃由蘇州旺山旺水生物醫藥股份有限公司（「本公司」）根據香港聯合交易所 有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09(2)條以及證券及期貨條 例（香港法例第571章）第XIVA部之內幕消息條文（定義見上市規則）而作出。 茲提述中國證券監督管理委員會（「中國證監會」）於2019年11月14日發佈並於 2023年8月10日進一步修訂的《H股公司境內未上市股份申請「全流通」業務指引》 （「指引」），內容有關H股於聯交所上市的公司申請非上市內資股（定義見指引）在 聯交所流通的程序。 根據指引，本公司董事（ ...

Core Viewpoint - ST Huaxi (002630.SZ) currently has no plans for share buybacks, indicating a focus on executing existing orders rather than increasing shareholder returns at this time [1] Group 1 - The company has stated that there is a time lag between signing orders and generating revenue, which suggests a need for patience in realizing financial results from current contracts [1] - The management team is actively working to promote the execution of existing orders, highlighting a commitment to operational efficiency and project delivery [1]

Group 1 - The core business of the company includes power station equipment and supporting infrastructure [1] - The company currently does not have any ultra-high voltage transmission and transformation projects [1]